Industry-First Bedside MRI Secures FDA 510(k) Clearance
Hyperfine’s portable MRI aimed at increasing imaging access and reducing cost.
Hyperfine Research, Inc.'s, first-in-industry portable MRI machine
Inpatients around the United States could soon experience the convenience of having an MRI scan without leaving their hospital rooms. The U.S. Food & Drug Administration announced Wednesday it has approved 510(k) clearance for Hyperfine Research, Inc.’s first-in-industry bedside MRI system.
This system is designed to improve MRI accessibility, bringing the technology to patients at almost any time in any environment. According to company data, the Hyperfine system costs 20-times less and weighs 10-times less than current conventional MRI machines. This portable system also consumes 35-times less power.
“More than 40 years after its first use, MRI remains a marvel. Unfortunately, it also remains inaccessible. It’s time that MRI made the jump to point-of-need just like X-ray and ultrasound have before it,” said Khan Siddiqui, M.D., Hyperfine’s chief medical officer, in a press statement. “Going beyond that, nearly 90 percent of the world has no access to MRI at all. With FDA’s decision, we are now ready to rewrite the rules of MRI accessibility.”
The 510(k) clearance approves usage for head imaging in patients ages 2 and over.
The system, which stands roughly 5-feet-tall with a 30-centimeter bore, can be wheeled throughout the hospital and directly into patient rooms. It plugs into a standard electrical wall outlet and is controlled with a wireless tablet.
Related Article: MRI Room Service: Portable Machine Brings In-Room Scans to Stroke Patients
In developing the system and testing its efficacy, Hyperfine performed thousands of brain scans through investigational partnerships at Yale New Haven Hospital, Penn Medicine, Good Samaritan Hospital Long Island, New York Presbyterian Brooklyn Methodist Hospital, and Brown University. Clinical results will be presented next week during the International Stroke Conference, scheduled for Feb. 19-21.
Device shipments will be available this summer, according to a press statement.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
